日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study

DURATION-8 研究评估了艾塞那肽每周一次联合达格列净、艾塞那肽每周一次或达格列净联合二甲双胍单药治疗对 2 型糖尿病患者体重、收缩压和甘油三酯的影响。

Jabbour, Serge A; Frías, Juan P; Guja, Cristian; Hardy, Elise; Ahmed, Azazuddin; Öhman, Peter

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial

在 DURATION-8 随机对照试验中,对 2 型糖尿病患者亚组分别采用艾塞那肽每周一次联合达格列净、艾塞那肽每周一次单独使用或达格列净单独加用二甲双胍单药治疗的效果进行了评估。

Frías, Juan P; Hardy, Elise; Ahmed, Azazuddin; Öhman, Peter; Jabbour, Serge; Wang, Hui; Guja, Cristian

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

在二甲双胍单药治疗控制不佳的 2 型糖尿病患者中,每周一次艾塞那肽联合每日一次达格列净与单独使用艾塞那肽或达格列净的安全性和有效性比较:DURATION-8 随机对照试验的 52 周结果

Jabbour, Serge A; Frías, Juan P; Hardy, Elise; Ahmed, Azazuddin; Wang, Hui; Öhman, Peter; Guja, Cristian